Therapeutic potential of phosphoinositide 3-kinase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 5, 2004, Pages 703-732

  Drees, Beth E ^a   Mills, Gordon B ^b   Rommel, Christian ^c   Prestwich, Glenn D ^a,d  

^a ECHELON BIOSCIENCES INC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Allergy; Cancer; Cardiovascular; Enzyme isoforms; High throughput screening; Immune response; Inflammation; Lipid kinase; Lipid phosphatase; Phosphatidylinositol polyphosphate; Signal transduction cascade

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE; FLAVONOID; FLUOROURACIL; GEMCITABINE; IC 87114; IC 980033; IMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; MYRICETIN; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PYRAN DERIVATIVE; PYRIMIDINE DERIVATIVE; QUERCETIN; QUINOLONE DERIVATIVE; STAUROSPORINE; TGX 127; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARDIOVASCULAR DISEASE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCRINE DISEASE; ENZYME INHIBITION; HUMAN; INFLAMMATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 2542606252     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.5.703     Document Type: Review

References (254)

1. MARTIN TFJ: Phosphoinositide lipids as signalling molecules: common themes for signal transduction, cytoskeletal regulation and membrane trafficking. Ann. Rev. Cell Dev. Biol. (1998) 14:231-264.
2. TOKER A, CANTLEY LC: Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature (1997) 387:673-676.
3. BALLA T. Pharmacology of phosphoinositides, regulators of multiple cellular functions. Curr. Pharm. Design (2001) 7:475-507.
4. 3: Complex roles at the cell surface. Cell (2000) 100:603-606.
5. CORVERA S: Phosphatidylinositol 3-kinase and the control of endosome dynamics: new players defined by structural motifs. Traffic (2001) 2:859-866.
6. IIJIMA M, HUANG Y, DEVREOTES P: Temporal and spatial regulation of chemotaxis. Devel. Cell (2002) 3:469-478.
7. COMER F, PARENT CA: PI 3-kinases and PTEN: how opposites chemoattract. Cell (2002) 109:541-544.
8. YIN HL, JANMEY PA: Phosphoinositide regulation of the actin cytoskeleton. Ann. Rev. Physiol (2003) 65:761-789.
9. LING K, DOUGHMAN R, FIRESTONE A, BUNCE M, ANDERSON RA:Type I γ phosphatidylinositol phosphate kinase targets and regulated focal adhesions. Nature (2002) 420:89-93.
10. MARTELLI AM, TABELLINI G, BORGATTI P et al: Nuclear lipids: new functions for old molecules? J. Cell. Biochem. (2003) 88:455-461.
11. CULLEN PJ, COZIER GE, BANTING G, MELLOR H: Modular phosphoinositide-binding domains - their role in signalling and membrane trafficking. Curr. Biol. (2001) 11:R882-R893.
12. PRESTWICH GD: Touching all the bases: inositol polyphosphate and phosphoinositide affinity probes from glucose. Acc. Chem. Res. (1996) 29:503-513.
13. PRESTWICH GD: Phosphoinositide signalling: from affinity probes to pharmaceutical targets. Chem. Biol. (in press).
14. LESLIE NR, BIONDI RM, ALESSI DR: Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. (2001) 101:2365-2380.
15. KANAHO Y, SUZUKI T: Phosphoinositide kinases as enzymes that produce versatile signalling lipids, phosphoinositides. J. Biochem. (2002) 131:503-509.
16. ANDERSON RA, BORONENKOV IV, DOUGHMAN SD, KUNZ J, LOIJENS JC: Phosphatidylinositol phosphate kinases, a multifaceted family of signalling enzymes. J. Biol. Chem. (1999) 274:9907-9910.
17. MACDOUGALL LK, DOMIN J, WATERFIELD MD: A family of phosphoinositide 3-kinases in drosophila identifies a new mediator of signal transduction. Curr. Biol. (1995) 5:1404-1415.
18. CARPENTER CL, CANTLEY LC: Phosphoinositide kinases. Curr. Opin. Cell Biol. (1996) 8:153-158.
19. DERMAN, MP, TOKER A, HARTWIG JH et al: The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C. J. Biol. Chem. (1997) 272:6465-6470.
20. RAMEH LE, CANTLEY LC: The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol. Chem. (1999) 274:8347-8350.
21. LEEVERS SJ, VANHAESEBROECK B, WATERFIELD MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell. Biol. (1999) 11:219-225.
22. VANHAESEBROECK B, LEEVERS SJ, AHMADI K et al: Synthesis and function of 3-phosphorylated inositol lipids. Ann. Rev. Biochem (2001) 70:535-602.
23. MAEHAMA T, DIXON J: PTEN: a tumour suppresor that functions as a phospholipid phosphatase. Trends Cell Biol. (1999) 9:125-128.
24. LESLIE NR, DOWNES CP: PTEN: the down side of PI 3-kinase signalling. Cell. Signal (2002) 14:285-295.
25. LIU Q, SASAKI T, KOZIERADZKI I et al: SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. (1999) 13:786-791.
26. WYMANN MP, PIROLA L, KATANAEV VL, BULGARELLILEVA G: Phosphoinositide 3-kinase signalling: no lipids. Biochem. Soc. Trans. (1999) 27:629-634.
27. COGGESHALL KM, NAKAMURA K, PHEE H: How do inhibitory phosphatases work? Mol. Immunol, (2002) 39:521-529.
28. COGGESHALL KM: Negative signalling in health and disease. Immunol. Res. (1999) 19:47-64.
29. HELGASON CD, ANTONCHUK J, BODNER C, HUMPHRIES RK: Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice. Blood (2003) 102:3541-3547.
30. MERLOT S, MEILI R, PAGLIARINI DJ et al: A PTEN-related 5-phosphatidylinositol phosphatase localized in the Golgi. J. Biol. Chem. (2003) 278:39866-39873.
31. LAPORTE J, BEDEZ F, BOLINO A, MANDEL JL: Myotubularins, a large disease-associated family of cooperating catalytically active and inactive phosphoinositides phosphatases. Hum. Mol. Genet. (2003) 12:R285-R292.
32. PHILLIPS WA, STCLAIR F, MUNDAY AD, THOMAS RJS, MITCHELL CA: Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumours. Cancer (1998) 83:41-47.
33. SHAYESTEH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21:99-102.
34. MA YY, WEI SJ, LIN YC et al: PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 19:2739-2744.
35. MAYO LD, DIXON JE, DURDEN DL, TONKS NK, DONNER DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. (2002) 277:5484-5489.
36. MAYO LD, DONNER DB: The PTEN, Mdm2, p53 tumour suppressor-oncoprotein network. Trends Biochem. Sci. (2002) 27:462-467.
37. LI J, YEN C, LIAW D et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (1997) 275:1943-1947.
38. TENG DH, HU R, LIN H et al.: MMAC1/PTEN mutations in primary tumour specimens and tumour cell lines. Cancer Res. (1997) 57:5221-5225.
39. SIMPSON L, PARSONS R: PTEN: life as a tumour suppressor. Exp. Cell Res. (2001) 264:29-41.
40. MAEHAMA T, DIXON JE: The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. (1998) 273:13375-13378.
41. SUZUKI A, DE LA POMPA JL, STAMBOLIC V et al.: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumour suppressor gene in mice. Curr. Biol. (1998) 8:1169-1178.
42. SUZUKI A, SASAKI T, MAK T, NAKANO T. Functional analysis of the tumour supressor gene, PTEN in murine B cells and keratinocytes. Biochem. Soc. Trans. (2004) 32:362-365.
43. WISHART MJ, DIXON JE: PTEN and myotubularin phosphatases: from 3-phosphoinoisitide dephosphorylation to disease. Trends Cell Biol. (2002) 12:579-585.
44. TRONCHERE H, BUJBELLO A, MANDEL JL, PAYRASTRE B: Implication of phosphoinositide phosphatases in genetic diseases: the case of myotubularin. Cell. Mol. Life Sci. (2003) 60:2084-2099.
45. YU J, ZHANG Y, MCILROY J et al.: Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. (1998) 18:1379-1387.
46. SKOLNIK EY, MARGOLIS B, MOHAMMADI M et al.: Cloning of PI 3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell (1991) 65:83-90.
47. HOLT KH, OLSON L, MOYE-ROWLEY WS, PESSIN JE: Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Mol. Cell. Biol. (1994) 14:42-49.
48. CARPENTER CL, AUGER KR, CHANUDHURI M et al: Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J. Biol. Chem. (1993) 268:9478-9483.
49. NOLTE RT, ECK MJ, SCHLESSINGER J, SHOELSON SE, HARRISON SC: Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat. Struct. Biol. (1996) 3:364-374.
50. PANAYOTOU G, BAX B, GOUT I et al.: Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain with a PDGF receptor phosphorylation site: structural features and analysis of conformational changes. Embo. J. (1992) 11:4261-4272.
51. SHOELSON SE, SIVARAJA M, WILLIAMS KP et al: Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation. Embo. J. (1993) 12:795-802.
52. 3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins. Cell (1995) 83:821-830.
53. RODRIGUEZ-VICIANA P, WARNE PH, VANHAESEBROECK B, WATERFIELD MD, DOWNWARD J: Activation of phosphoinositide 3-kinase by interaction with ras and by point mutation. EMBO J. (1996) 15:2442-2451.
54. JIMENEZ C, HERNANDEZ C, PIMENTEL B, CARRERA AC: The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J. Biol. Chem. (2002) 277:41556-41562.
55. REMILLARD B, PETRILLO R, MASLINSKI W et al.: Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J. Biol. Chem. (1991) 266:14167-14170.
56. GONZALEZ-GARCIA A, MERIDA I, MARTINEZ AC, CARRERA AC: Intermediate affinity interleukin-2 receptor mediates survival via a phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem. (1997) 272:10220-10226.
57. CIPRES A, CARRASCO S, MERIDA I: Deletion of the acidic-rich domain of the IL-2Rβ chain increases receptor-associated PI 3-K activity. FEBS Lett. (2001) 500:99-104.
58. CUEVAS BD, LU Y, MAO M et al.: Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. (2001) 276:27455-27461.
59. KODAKI T, WOSCHOLSKI R, HALLBERG B et al.: The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. (1994) 4:798-806.
60. LEMMON MA: Phosphoinositide recognition domains. Traffic (2003) 4:201-213.
61. FRANKE TF, YANG SI, CHAN TO et al.: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 81:727-736.
62. DATTA K, BELLACOSA A, CHAN TO, TSICHLIS PN: Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. (1996) 271:30835-30839.
63. BRAZIL DP, HEMMINGS BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. (2001) 26:657-664.
64. SHEN F, WEBER G: Synergistic action of quercetin and genisein in human ovarian carcinoma cells. Oncol. Res. (1997) 9:597-602.
65. WEBER G, SHEN F, LI W et al.: Signal transduction and biochemical targeting of ovarian carcinoma. Eur. J. Gynaecol. Oncol. (2000) 21:231-236.
66. WEBER G, SHEN F, PRAJDA N, YANG H, LI W. Amplification of signal transduction capacity and downregulation by drugs. Adv. Enzyme Reg. (1999) 39:51-66.
67. SHISHEVA A: Regulating GLUT4 vesicle dynamics by phosphoinositide kinases and phosphoinositide phosphatases. Front. Biosci. (2003) 8:S945-S967.
68. MAFFUCCI T, BRANCACCIO A, PICCOLO E, STEIN RC, FALASCA M: Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J. (2003) 22:4178-4189.
69. SATO T, OVERDUIN M, EMR SD: Location, location, location: membrane targeting directed by PX domains. Science (2001) 294:1881-1885.
70. PETIOT A, FAURE J, STENMARK H, GRUENBERG J: PI3P signalling regulates receptor sorting but not transport in the endosomal pathway. J. Cell Biol. (2003) 162:971-979.
71. HOWE CL, MOBLEY WC: Signalling endosome hypothesis: a cellular mechanism for long distance communication. J. Neurobiol. (2004) 58:207-216.
72. CANTLEY LC: The phosphoinositide 3-kinase pathway. Science (2002) 296:1655-1657.
73. LUO J, MANNING B, CANTLEY L: Targeting the PI 3-K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 4:257-262.
74. CHANG F, LEE JT, NAVOLANIC PM et al.: Involvement of PI 3-K/Akt pathway in cell cycle progression, apoptosis and neoplastic transformation: a target for cancer chemotherapy. Leukaemia (2003) 17:590-603.
75. VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev. Cancer (2002) 2:489-501.
76. SAUSVILLE E, ELSAYED Y, MONGA M, KIM G: Signal transduction-directed cancer treatments. Ann. Rev. Pharmacol. Toxicol. (2003) 43:199-231.
77. 3 and Gβγ-regulated guanine nucelotide exchange factor for Rac. Cell (2002) 108:809-821.
78. SHINOHARA M, TERADA Y, IWAMATSU A et aL: SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature (2002) 416:759-763.
79. HAN J, LUBY-PHELPS K, DAS B et al.: Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science (1998) 279:558-560.
80. WELCH HCE, COADWELL WJ, STEPHENS LR, HAWKINS PT: Phosphoinositide 3-kinase-dependent activation of Rac. Febs. Lett. (2003) 546:93-97.
81. KOZIKOWSKI AP, SUN H, BROGNARD J, DENNIS PA: Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. (2003) 125:1144-1145.
82. MEUILLET E, MAHADEVAN D, VANKAYALAPATI H et al.: Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phoshatidyl-myoinositol analogues. Molec. Cancer Ther. (2003) 2:389-399.
83. KONDAPAKA SB, SINGH RP, DASMAHAPATRA G, SAUSVILLE E, ROY K: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Molec. Cancer Ther. (2003) 2:1093-1103.
84. REUVENI H, LIVNAH N, GIEIGER T et al.: Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry (2002) 41:10304-103314.
85. FUJITA N, TSURUO T: Survival-signalling pathway as a promising target for cancer chemotherapy. Cancer Chemother. Pharmacol. (2003) 52:S24-S28.
86. GAO N, ZHANG Z, JIANG BH, SHI XL: Role of PI 3-K/AKT/mTOR signalling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. (2003) 310:1124-1132.
87. HARRIS T, LAWRENCE J Jr: TOR Signalling. Sci. STKE (2003) 212:15.
88. DANCEY J, SAUSVILLE E: Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Drug Discov. (2003) 2:296-313.
89. SCHMID AC, WOSCHOLSKI R: Phosphatases as small-molecule targets: inhibiting the endogenous inhibitors of kinases. Biochem. Soc. Trans. (2004) 32:348-349.
90. RONG R, AHN J-Y, HUANG H et al.: PI 3-K enhancer-homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat. Neurosci. (2003) 6:1153-1161.
91. DAVIES G, BYRNE R, WOSCHOLSKI R: Characterisation of an activator of phosphoinositide 3-kinase. Biochem. Soc. Trans. (2004) (in press).
92. MISRA S, MILLER G, HURLEY JH: Recognizing phosphatidylinositol 3-phosphate. Cell (2001) 107:559-562.
93. RONG SB, HU YH, ENYEDY I et al.: Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J. Med. Chem (2001) 44:898-908.
94. REBECCHI MJ, SCARLATA S: Pleckstrin homology domains: a common fold with diverse functions. Ann. Rev. Biophys. Biomol. Struct. (1998) 27:503-528.
95. HURLEY JH, ANDERSON D, BEACH B et al.: Structural genomics and signalling domains. Trends Biochem. Sci. (2002) 27:48-53.
96. HURLEY JH, TSUJISHITA Y, PEARSON MA: Floundering about at cell membranes: a structural view of phospholipid signalling. Curr. Opin. Struct. Biol. (2000) 10:737-743.
97. THEIBERT AB, ESTEVEZ VA, FERRIS CD et al.: Inositol 1,3,4,5-tetrakisphosphate and inositol hexakisphosphate receptor proteins: isolation and characterization from rat brain. Proc. Natl. Acad. Sci. USA (1991) 88:3165-3169.
98. RAO VR, CORRADETTI MN, CHEN JA et al.: Expression cloning of protein targets for 3-phosphorylated phosphoinositides. J. Biol. Chem. (1999) 274:37893-37900.
99. KRUGMANN S, ANDERSON KE, RIDLEY SH et al.: Identification of ARAP3, a novel PI 3-K effector regulating both Arf and Rho GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell (2002) 9:95-108.
100. ZEWAIL A, XIE MW, XING Y et al.: Novel functions of the phosphatidylinositol metabolic pathway discovered by a chemical genomics screen with wortmannin. Proc. Nat. Acad. Sci. USA (2003) 100:3345-3350.
101. VANHAESEBROECK B, WATERFIELD MD: Signalling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. (1999) 253:239-254.
102. OTSU M, HILES I, GOUT I et al.: Characterization of two 85 kD proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes and PI 3-kinase. Cell (1991) 65:91-104.
103. HILES ID, OTSU M, VOLINIA S et al.: Phosphatidylinositol 3-kinase: structure and expression of the 110 kD catalytic subunit. Cell (1992) 70:419-429.
104. FU Z, ARONOFF-SPENCER E, BACKER JM, GERFEN GJ: The structure of the inter-SH2 domain of Class IA phosphoinositide 3-kinase determined by site-directed spin labelling EPR and homology modeling. Proc. Natl. Acad. Sci. USA (2003) 100:3275-3280.
105. CHAN TO, RODECK U, CHAN AM et al.: Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1:181-191.
106. VOLINIA S, PATRACCHINI P, OTSU M et al.: Chromosomal localization of human p85α, a subunit of phosphatidylinositol 3-kinase and its homologue p85β. Oncogene (1992) 7:789-793.
107. VOLINIA S, HILES I, ORMONDROYD E et al.: Molecular cloning, cDNA sequence and chromosomal localization of the human phosphatidylinositol 3-kinase p110α (PIK3CA) gene. Genomics (1994) 24:472-477.
108. KNUUTILA S, BJORKQVIST AM, AUTIO K, TARKKANEN M, WOLF M: DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am. J. Pathol. (1998) 152:1107-1123.
109. ZHANG L, YANG N, KATSAROS D et al.: The oncogene phosphatidylinositol 3′-kinase catalytic subunit α promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res. (2003) 63:4225-4231.
110. YUAN ZQ, SUN M, FELDMAN RI et al.: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 19:2324-2330.
111. HU L, HOFMANN J, LU Y, MILLS GB, JAFFE RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. (2002) 62:1087-1092.
112. HU L, ZALOUDEK C, MILLS GB, GREY J, JAFFE RB:.In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY-294002). Clin. Cancer Res. (2000) 6:880-886.
113. MASSION PP, KUO WL, STOKOE D et al.: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. (2002) 62:3636-3640.
114. TSAO AS, MCDONNELL T. LAM S et al.: Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol. Biomarkers Prev. (2003) 12:660-664.
115. 2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival. J. Biol. Chem. (2003) 278:23630-23638.
116. ROYMANS, D, SLEGERS, H: Phosphatidylinositol 3-kinases in tumour progression. Eur. J. Biochem. (2001) 268:487-498.
117. STEIN RC, WATERFIELD MD: PI 3-Kinase inhibition: a target for drug development? Mol. Med Today (2000) 6:347-357.
118. WORKMAN P: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem. Soc. Trans. (2004) 32:393-396.
119. WARD S, SOTSIOS Y, DOWDEN J, BRUCE I, FINAN P: Therapeutic potential of review phosphoinositide 3-kinase inhibitors. Chem. Biol. (2003) 10:207-213.
120. WEAVER SA, WARD SG: Phosphoinositide 3-kinases in the gut: a link between inflammation and cancer? Trends Mol. Med. (2001) 7:455-462.
121. MILLS GB, KOHN E, LU Y et al.: Linking molecular diagnostics to molecular therapeutics: targeting the PI 3-K pathway in breast cancer. Semin. Oncol. (2003) 30:93-104.
122. MILLS GB, LU Y, FANG X et al.: The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumourigenesis, prognosis and therapy. Semin Oncol. (2001) 28:125-141.
123. JACKSON SP, YAP CL, ANDERSON KE: Phosphoinositide 3-kinases and the regulation of platelet function. Biochem. Soc. Trans. (2004) 32:387-392.
124. ROCHE S, DOWNWARD J, RAYNAL P, COURTNEIDGE SA: A function for phosphatidylinositol 3-kinase β (p85α-p110β) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol. Cell. Biol. (1998) 18:7119-7129.
125. LEVERRIER Y, OKKENHAUG K, SAWYER C et al.: Class I phosphoinositide 3-kinase p110β is required for apoptotic cell and Fc γ receptor-mediated phagocytosis by macrophages. J. Biol. Chem. (2003) 278:38437-38442.
126. STOYANOV B, VOLINIA S, HANCK T et al.: Cloning and characterization of a G-protein-activated human phosphoinositide-3 kinase. Science (1995) 269:690-693.
127. BROCK C, SCHAEFER M, REUSCH HP et al.: Roles of Gβγ in membrane recruitment and activation of p11Oγ/p101 phosphoinositide 3-kinase γ. J. Cell Biol. (2003) 160:89-99.
128. WANG Q, LI N, WANG X, KIM MM, EVERS BM: Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res. (2002) 8:1940-1947.
129. WEINER OD, NEILSEN PO, PRESTWICH GD et al.: A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat. Cell Biol. (2002) 4:509-512.
130. RICKERT P, WEINER OD, WANG F, BOURNE HR, SERVANT G: Leukocytes; navigate by compass: roles of PI 3-K γ and its lipid products. Trends Cell Biol. (2000) 10:466-473.
131. WYMANN MP, BJORKLOF K, CALVEZ R et al.: Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. (2003) 31:275-280.
132. SASAKI T, IRIE-SASAKI J, JONES RG et al.: Function of PI 3-K γ in thymocyte development, T cell activation and neutrophil migration. Science (2000) 287:1040-1046.
133. SASAKI T, SUZUKI A, SASAKI J, PENNINGER JM: Phosphoinositide 3-kinases in immunity: Lessons from knockout mice. J. Biochem. (2002) 131:495-501.
134. HIRSCH E, KATANAEV VL, GARLANDA C et al.: Central role for G-protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science (2000) 287:1049-1053.
135. LI Z, JIANG H, XIE W et al.: Roles of PLC-β2 and -β3 and PI 3-Kγ in chemoattractant-mediated signal transduction. Science (2000) 287:1046-1049.
136. WYMANN MP, ZVELEBIL M, LAFFARGUE M: Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol. Sci. (2003) 24:366-376.
137. SASAKI T, IRIESASAKI J, HORIE Y et al.: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)K γ. Nature (2000) 406:897-902.
138. BARBIER M, ATTOUB S, CALVEZ R et al.: Tumour biology. Weakening link to colorectal cancer? Nature (2001) 413:796.
139. SASAKI T, IRIE-SASAKI J, HORIE Y et al.: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ. Nature (2003) 426:584.
140. CHANTRY D, VOJTEK A, KASHISHIAN A et al.: p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. (1997) 272:19236-19241.
141. OKKENHAUG K, BILANCIO A, FARJOT G et al.: Impaired B and T cell antigen receptor signalling in pl10δ PI 3-kinase mutant mice. Science (2002) 297:1031-1034.
142. CLAYTON E, BARDI G, BELL SE et al.: A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med (2002) 196:753-763.
143. JOU ST, CARPINO N, TAKAHASHI Y et al.: Essential, non-redundant role for the phosphoinositide 3-kinase p110δ in signalling by the B cell receptor complex. Mol. Cell. Biol. (2002) 22:8580-8591.
144. SADHU C, MASINOVSKYB, DICK K, SOWELL C, STAUNTON DE: Essential role of PI 3-K δ in neutrophil directional movement. J. Immunol. (2003) 170:2647-2654.
145. SADHU C, DICK K, TINO WT, STAUNTON DE: Selective role of PI 3-K delta in neutrophil inflammatory esponses. Biochem. Biophys. Res. Commun. (2003) 308:764-769.
146. SAWYER C, STURGE J, BENNETT DC et al.: Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110 delta. Cancer Res. (2003) 63:1667-1675.
147. PRESTWICH GD: Inhibitors of phosphatidylinositol 3-kinase: importance in receptor signalling. Chemtracts Org. Chem. (1994) 7:301-305.
148. POWIS G, BONJOUKLIAN R, BERGGREN MM et al.: Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3- kinase. Cancer Res. (1994) 54:2419-2423.
149. MATTER WF, BROWN RF, VLAHOS CJ: The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res. Commun. (1992) 186:624-631.
150. VLAHOS CJ, MATTER WF, HUI KY, BROWN RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H- I-benzopyran-4-one (LY-294002). J. Biol. Chem. (1994) 269:5241-5248.
151. WYMANN MP, BULGARELLI-LEVA G, ZVELEBIL MJ et al.: Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. (1996) 16:1722-1733.
152. DAVIES SP, REDDY H, CAIVANO M, COHEN P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. (2000) 351:95-105.
153. WALKER EH, PERISIC O, RIED C, STEPHENS L, WILLIAMS RL: Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (1999) 402:313-320.
154. PACOLD ME, SUIRE S, PERISIC O et al.: Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell (2000) 103:931-943.
155. WALKER EH, PACOLD ME, PERISIC O et al.: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY-294002, quercetin, myricetin and staurosporine. Mol. Cell (2000) 6:909-919.
156. DJORDJEVIC S, DRISCOLL PC: Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem. Sci. (2002) 27:426-432.
157. LEE JS, HMAMA Z, MUI A, REINER NE: Stable gene silencing in human monocytic cell lines using lentiviral-delivered siRNA. silencing of the pl1Oα isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1α, 25-dihydroxycholecalciferol and bacterial lipopolysaccharide. J. Biol. Chem. (2003) 12:12.
158. CZAUDERNA F, SANTEL A, HINZ M et al.: Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. (2003) 31:e127.
159. ROCHE S, DHAND R, WATERFIELD MD, COURTNEIDGE SA: The catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor but not for middle-T antigen pp6O (c-src) complexes. Biochem. J. (1994) 301:703-711.
160. VANHAESEBROECK B, JONES GE, ALLEN WE et al.: Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat. Cell. Biol. (1999) 1:69-71.
161. MCMULLEN, JR, SHIOI, T, HUANG WY et al.: The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110α) pathway. J. Biol. Chem. (2004) 279:4782-4793.
162. MCMULLEN JR, SHIOI T, ZHANG L et al.: Phosphoinositide 3-kinase (P110α) plays a critical role for the induction of physiological but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. USA (2003) 100:12355-12360.
163. BENISTANT C, CHAPUIS H, ROCHE S: A specific function for phosphatidylinositol 3-kinase alpha (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α -p110β) in de novo DNA synthesis of human colon carcinoma cells. Oncogene (2000) 19:5083-5090.
164. WINDMILLER DA, BACKER JM: Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus Fc ε RI receptors. J. Biol. Chem. (2003) 278:11874-11878.
165. ARCARO A, KHANZADA UK, VANHAESEBROECK B et al.: Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J. (2002) 21:5097-5108.
166. TESTA JR, BELLACOSA A: AKT plays a central role in tumourigenesis. Proc. Natl. Acad. Sci. USA (2001) 98:10983-10985.
167. CHANG HW, AOKI M, FRUMAN D et al.: Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 276:1848-1850.
168. AOKI M, SCHETTER C, HIMLY M et al.: The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J. Biol. Chem. (2000) 275:6267-6275.
169. JIMENEZ C, JONES DR, RODRIGUEZ-VICIANA P et al.: Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. J. Biol. Chem. (2000) 275:6267-6275.
170. BORLANDO L, REDONDO C, ALVAREZ B et al.: Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumour generation in vivo. EMBO J. (1998) 17:743-753.
171. PHILIP AJ, CAMPBELL IG, LEET C et al.: The phosphatidylinositol 3′-kinase p85 α gene is an oncogene in human ovarian and colon tumours. Cancer Res. (2001) 61:7426-7429.
172. SHENG H, SHAO J, TOWNSEND CM, EVERS BM: Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut (2003) 52:1472-1478.
173. ALI IU, SCHRIML LM, DEAN M: Mutational spectra of PTEN/MMAC1 gene: a tumour suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. (1999) 91:1922-1932.
174. PERREN A, WENG LP, BOAG AH et al.: Immumohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. (1999) 155:1253-1260.
175. BOSE S, CRANE A, HIBSHOOSH H et al.: Reduced expression of PTEN correlates with breast cancer progression. Human Pathol. (2002) 22:405-409.
176. LIAW D, MARSH DJ, LI J et al.: Germ line mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. (1997) 16:64-67.
177. BROGNARD J, CLARK AS, NI Y, DENNIS PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. (2001) 61:3986-3997.
178. PERUGINI RA, MCDADE TP, VITTIMBERGA FJ Jr., CALLERY MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J. Surg. Res. (2000) 90:39-44.
179. BONDAR VM, SWEENEY-GOTSCH B, ANDREEFF M, MILLS GB, MCCONKEY DJ: Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. (2002) 1:989-997.
180. SHINGU T, YAMADA K, HARA N et al.: Growth inhibition of human malignant glioma cells induced by the PI 3-K-specific inhibitor. J. Neurosurg. (2003) 98:154-161.
181. SEMBA S, ITOH N, ITO M, HARADA M, YAMAKAWA M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY-294002), a specific inhibitor of phosphatidylinositol 3′ -kinase, in human colon cancer cells. Clin. Cancer Res. (2002) 8:1957-1963.
182. BRENNAN P, MEHL AM, JONES M, ROWE M: Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene (2002) 21:1263-1271.
183. +/- mice. Proc. Natl. Acad. Sci. USA (2001) 98:10320-10325.
184. MILLS GB, LU Y, KOHN EC: Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/ TOR component of the PI 3-K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2001) 98:10031-10033.
185. NAKANISHI K, SAKAMOTO M, YASUDA J et al.: Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. (2002) 62:2971-2975.
186. NICHOLSON KM, QUINN DM, KELLETT GL, WARR JR: LY-294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multi-drug resistant cells. Cancer Lett. (2003) 190:31-36.
187. BORTUL R, TAZZARI PL, CAPPELLINI A et al.: Constitutively active Akt1 protects HL60 leukaemia cells from TRAIL-induced apoptosis through a mechanism involving NF-KB activation and cFLIP(L) upregulation. Leukaemia (2003) 17:379-389.
188. MARTELLI AM, TAZZARI PL, TABELLINI G et al.: A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid and ionizing radiation of hmnan leukaemia cells. Leukaemia (2003) 17:1794-1805.
189. CHEN X, THAKKAR H, TYAN F et al.: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene (2001) 20:6073-6083.
190. JOY AM, BEAUDRY CE, TRAN NL et al.: Migrating glioma cells activate the PI 3-K pathway and display decreased susceptibility to apoptosis. J. Cell Sci. (2003) 116:4409-4417.
191. LU Y, LIN YZ, LAPUSHIN R et al.: The PTEN/MMAC1/TEP tumour suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene (1999) 18:7034-7045.
192. DAVIES M, LU Y, SANO T et al.: Adenoviral transgene expression of MMAC/ PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. (1998) 58:5285-5290.
193. BIANCO R, SHIN I, RITTER CA et al.: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumour cells counteracts the antitumour action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 22:2812-2822.
194. NG SS, TSAO MS, NICKLEE T, HEDLEY DW. Wortmannin inhibits PKB/Akt phosphorylation and promotes gemcitabine antitumour activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. (2001) 7:3269-3275.
195. YIP-SCHNEIDER MT, WIESENAUER CA, SCHMIDT CM: Inhibition of the phosphatidylinositol 3′-kinase signalling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J. Gastrointest. Surg. (2003) 7:354-363.
196. ZHOU B, HU M, MILLER S et al.: Her-2/neu blocks tumour necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. (2000) 275:8027-8031.
197. O'GORMAN DM, MCKENNA SL, MCGAHON AJ, KNOX KA, COTTER TG: Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI 3-kinase survival signals. Leukaemia (2000) 14:602-611.
198. O'GORMAN DM, MCKENNA SL, MCGAHON AJ, COTTER TG: Inhibition of PI 3-Kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway. Leuk. Res. (2001) 25:801-811.
199. CLARK AS, WEST K, STREICHER S, DENNIS PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab or tamoxifen in breast cancer cells. Mol. Cancer Ther. (2002) 1:707-717.
200. YANG JM, VASSIL A, HAIT WN: Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multi-drug resistant carcinoma cells. Biochem. Pharmacol. (2002) 63:959-966.
201. KRYSTAL GW, SULANKE G, LITZ J: Inhibition of phosphatidylinositol 3-kinase-Akt signalling blocks growth, promotes apoptosis and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol. Cancer Ther. (2002) 1:913-922.
202. HESS AR, SEFTOR EA, SEFTOR REB, HENDRIX MJC: Phosphoinositide 3-kinase regulates membrane Type 1 -matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res. (2003) 63:4757-4762.
203. LIANG K, JIN W, KNUEFERMANN C et al.: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol. Cancer Ther. (2003) 2:353-360.
204. EDWARDS E, GENG L, TAN J et al.: Phosphatidylinositol 3-kinase/Akt signalling in the response of vascular endothelium to ionizing radiation. Cancer Res. (2002) 62:4671-4677.
205. WETZKER R, ROMMEL C: Phosphoinositide 3-kinases and targets for therapeutic intervention. Curr. Pharmaceut. Design (in press).
206. THELEN M, WYMANN MP, LANGEN H: Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signalling in neutrophil leukocytes. Proc. Natl. Acad. Sci. USA (1994) 91:4960-4964.
207. LAFFARGUE M, CALVEZ R, FINAN P et al.: Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity (2002) 16:441-451.
208. PAGES F, RAGUENEAU M, ROTTAPEL R et al.: Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T cell signalling. Nature (1994) 369:327-329.
209. RUDD CE: Upstream-downstream: CD28 cosignalling pathways and T cell function. Immunity (1996) 4:527-534.
210. LU Y, CUEVAS B, GIBSON S et al.: Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J. Immunol. (1998) 161:5404-5412.
211. FRASER JD, IRVING BA, CRABTREE GR, WEISS A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science (1991) 251:313-316.
212. OKKENHAUG K, VANHAESEBROECK B: PI 3-K-signalling in B- and T cells: insights from genetargeted mice. Biochem. Soc. Trans. (2003) 31:270-274.
213. HELGASON CD, DAMEN JE, ROSTEN P et al.: Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology and a shortened lifespan. Genes Dev. (1998) 12:1610-1620.
214. KIM CH, HANGOC G, COOPER S et al.: Altered responsiveness to chemokines due to targeted disruption of SHIP. J. Clin. Invest. (1999) 104:1751-1759.
215. CRACKOWER MA, OUDIT GY, KOZIERADZKI I et al.: Regulation of myocardial contractility and cell size by distinct PI 3-K-PTEN signalling pathways. Cell (2002) 110:737-749.
216. SATA M, NAGAI R: Phosphatidylinositol 3-kinase: a key regulator of vascular tone? Circ. Res. (2002) 91:273-275.
217. JIANG GQ, ZHANG B: PI 3-kinase and its up- and downstream modulators as potential targets for the treatment of Type II diabetes. Front. Biosci. (2002) 7:904-917.
218. WARD SG: Measurement of phosphoinositide 3-kinase activity. In: Chemokine Protocols. Proudfoot AEI, Wells TNC, Power CA (Eds) Humana Press Inc, NJ, USA (2000) 138:163-172.
219. PRESTWICH GD, CHEN R, FENG L et al.: In situ detection of phospholipid and phosphoinositide metabolism. Adv. Enzyme Reg. (2002) 42:19-38.
220. OGANESIAN A, POOT M, DAUM G et al.: Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation. Proc. Natl. Acad. Sci. USA (2003) 100:7563-7568.
221. FUCHIKAMI K, TOGAME H, SAGARA A et al.: Rapid radioactive assay for PI 3-K. J. Biomol. Screen (2002) 7:441-550.
222. GRAY A, OLSSON H, BATTY IH, PRIGANICA L, DOWNES CP: Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signalling lipids in cell and tissue extracts. Anal. Biochem. (2003) 313:234-245.
223. DREES BE, WEIPERT A, HUDSON H et al.: Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. Comb. Chem. High Throughput Scr. (2003) 6:321-330.
224. 3). J. Org. Chem. (1996) 61:6305-6312.
225. 2 concentration monitored in living cells. Curr. Biol. (1998) 8:343-346.
226. BALLA T, BONDEVA T, VARNAI P: How accurately can we image inositol lipids in living cells? Trends Pharmacol. Sci. (2000) 21:238-241.
227. SATO M, UEDA Y, TAKAGI T, UMEZAWA Y: Production of PtdInsp3 at endomembranes is triggeredby receptor endocytosis. Nat. Cell Biol. (2003) 11:1016-1022.
228. DOWLER S, CURRIE RA, CAMPBELL DG et al.: Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. Biochem. J. (2000) 351:19-31.
229. 2 and the multi-PDZ-domain-containing protein MUPP1 in vivo. Biochem. J. (2002) 361:525-536.
230. WATT SA, KIMBER WA, FLEMING IN et al.: Detection of novel intracellular agonist responsive pools of phosphatidylinositol 3,4-bisphosphate using the TAPP1 pleckstrin homology domain in immunoelectron microscopy. Biochem. J. (2004) 377:653-663.
231. OZAKI S, DEWALD DB, SHOPE JC, CHEN J, PRESTWICH GD: Intracellular delivery of phosphoinositides and inositol phosphates using polyamine carriers. Proc. Natl. Acad Sci. USA (2000) 97:11286-11291.
232. 2 is required for PKB phosphorylation at Ser473. Studies using cells from SHIP knockout mice. J. Biol Chem. (2002) 277:9027-9035.
233. CHEN RY, KANG VH, CHEN J et al.: A monoclonal antibody to visualize Ptdlns(3,4,5)P-3 in cells. J. Histochem. Cytochem. (2002) 50:697-708.
234. NISWENDER K, GALLIS B, BLEVINS J et al: Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. J. Histochem. Cytochem. (2003) 51:275-283.
235. ARCARO A, WYMANN MP: Wortmannin is a potent phoshatidylinositol 3-phosphate inhibitor: the role of phosphaditylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. (1993) 296:297-301.
236. HOLLERAN JL, EGORIN MJ, ZUHOWSKI EG et al.: Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal. Biochem. (2003) 323:19-25.
237. CREEMER LC, KIRST HA, VLAHOS CJ, SCHULTZ RM: Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase. J. Med. Chem (1996) 39:5021-5024.
238. HU YH, MEUILLET EJ, BERGGREN M, POWIS G, KOZIKOWSKI AP: 3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. Bioorg Med. Chem. Lett. (2001) 11:173-176.
239. QIAO LX, NAN FJ, KUNKEL M et al.: 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signalling and cancer cell growth. J. Med. Chem. (1998) 41:3303-3306.
240. RUITER G, ZERP S, BARTELINK H, VAN BLITTERSWIJK W, VERHEIJ M: Anticancer alkyllysophospholipids inhibit the phosphatidylinositol-3-kinase-Akt/PKB survival pathway. Anticancer Drugs (2003) 14(2):167-173.
241. WARD S, MILLS S, LIU C, WESTWICK J, POTTER BVL: D-Myo-Inositol 1,4,5-trisphosphate analogues modified at the 3-position inhibit phosphatidylinositol 3-kinase. J. Biol. Chem. (1995) 270:12075-12084.
242. WANG DS, CHEN CS: Synthesis and biological evaluation of L-α-phosphatidyl-D-3-deoxy-3-heteromethyl-myo-inositols as phosphoinositide 3-kinase inhibitors. Bioorg. Med. Chem. (2001) 9:3165-3172.
243. CONDLIFFE AM, CADWALLADER KA, WALKER TR et al.: Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells. Respir Res. (2000) 1 :24-29.
244. ROCHE S, KOEGL M, COURTNEIDGE SA: The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some but not all, growth factors. Proc. Natl. Acad. Sci., USA (1994) 91:9185-9189.
245. TAN J, HALLAHAN DE: Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res. (2003) 63:7663-7667.
246. MILLS GB, MOOLENAAR W. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer (2003) 3:582-591.
247. FENG L, MILLS GB, PRESTWICH GD: Modulators of lysophosphatidic acid signalling. Expert Opin. Ther. Patents(2003) 13:1619-1634.
248. 1-protein-coupled receptors. EMBO J. (1999) 18:386-395.
249. TANYI J, MORRIS A, WOLF J et al.: The human lipid phosphate phosphatase-3 decreases the growth, survival and tumourigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signalling cascade as a target for therapy in ovarian cancer. Cancer Res. (2003) 63:1073-1082.
250. JOHNSON Z, POWER CA, WEISS C et al.: Chemokine inhibition - why, when, where, which and how? Biochem. Soc. Trans. (2004) 32:366-377.
251. FINAN PM, THOMAS MJ: PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem. Soc. Trans. (2004) 32:378-382.
252. ALLOATTI G, MONTRUCCHIO G, LEMBO G, HIRSCH E: Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease. Biochem. Soc. Trans. (2004) 32:378-382.
253. OKKENHAUG K, BILANCIO A, EMERY JL, VANHAESEBROECK B: Phosphoinositide 3-kinase in T cell activation and survival. Biochem. Soc. Trans. (2004) 32:383-386.
254. HAYFLICK J, PURI K, DOUANGPANYA J et al.: Role of PI 3-K p110δ in leukocyte function. Biochem. Soc. Trans. (in press).